Page last updated: 2024-10-30

losartan and Leukemia, Myeloid, Acute

losartan has been researched along with Leukemia, Myeloid, Acute in 1 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Mansour, RSH1
Al Khawaja, AY1
Hamdan, II1
Khalil, EA1

Other Studies

1 other study available for losartan and Leukemia, Myeloid, Acute

ArticleYear
IR microspectroscopic investigation of the interaction of some losartan salts with human stratum corneum protein and its effect on losartan transdermal permeation.
    PloS one, 2023, Volume: 18, Issue:6

    Topics: Amlodipine; Humans; Keratins; Leukemia, Myeloid, Acute; Losartan; Pharmaceutical Preparations; Salts

2023